| 体内研究: |
Bezuclastinib (25 mg/kg, 口服, 3 天) 在大鼠中显示脑:血浆比率为 0.07。 |
| 参考文献: |
1. Guarnieri A, et al. Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance. Blood. 2021, 138: 4595. 2. Guarnieri A, et al. Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration. MOLECULAR CANCER THERAPEUTICS. 2021, 20(12). |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0 ml |
0 ml |
0 ml |
| 5 mM |
0 ml |
0 ml |
0 ml |
| 10 mM |
0 ml |
0 ml |
0 ml |
| 50 mM |
0 ml |
0 ml |
0 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |